Base de datos : IBECS
Búsqueda : "Allergol. immunopatol" [Revista]
Referencias encontradas : 1742 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 175 va a la página                         

  1 / 1742 IBECS  
              next record last record
selecciona
para imprimir
Texto Completo
Texto Completo
Id: 203463
Autor: Barrios, Yvelise; Franco, Andrés; Alava-Cruz, Cristina; Cuesta-Martin, Ricardo; Camara, Carmen; Matheu, Victor.
Título: Easy approach to detect cell immunity to COVID vaccines in common variable immunodeficiency patients
Fuente: Allergol. immunopatol;50(3):101-105, 2022. ilus, tab.
Idioma: en.
doi: 10.15586/aei.v50i3.583.
Resumen: Background Patients with primary antibody deficiencies, such as Common Variable Immunodeficiency (CVID), have some problems to assess immune response after coronavirus disease (COVID) vaccination. Cutaneous delayed-type hypersensitivity (DTH) has the potential to be used as a useful, simple, and cheaper tool to assess T-cell (T lymphocyte) function.Methods Seventeen patients with CVID, a rare disease, received two doses of the mRNA-based Pfizer-BioNTech COVID-19 vaccine. Humoral Immune Response (HIR) was determined by measuring specific immunoglobulin G (IgG) antibodies, and Cellular Immune Response (CIR) was evaluated using an ex vivo interferon-gamma release assay (IGRA) and in vivo by DTH skin test.Results Two weeks after the second dose of the vaccine, 12 out of 17 CVID patients have high optical density (OD) ratios of specific anti-spike protein (S) IgG whereas five patients were negative or low. Ex vivo CIR was considered positive in 14 out of 17 S1-stimulated patients. Unspecific stimulation was positive in all 17 patients showing no T-cell defect. A positive DTH skin test was observed in 16 CVID patients. The only patient with negative DTH also had negative ex vivo CIR.Conclusions The use of DTH to evaluate CIR was validated with an optimal correlation with the ex vivo CIR. The CIR after vaccination in patients with antibody deficiencies seems to have high precision and more sensitivity to antibodies-based methods in CVID.Clinical Implications There is a remarkable correlation between cutaneous DTH and ex vivo IGRA after COVID vaccination. A COVID-specific skin DTH test could be implemented in large populations.Capsule Summary Cutaneous delayed-type hypersensitivity has the potential to be used as a useful, simple, and cheaper tool to assess T-cell functioning (AU)
Descriptores: inmunodeficiencia variable común
neumonía vírica/prevención & control
pandemias
infecciones por Coronavirus/prevención & control
-anticuerpos víricos
inmunidad celular
inmunidad humoral
inmunoglobulina G
glicoproteína de las espículas de coronavirus
vacunación
Límites: seres humanos
Tipo de Publicación: revisión
Responsable: ES15.1 - BNCS


  2 / 1742 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Texto Completo
Id: 203462
Autor: Shuiping, Yan; Si, Ai; Lizhen, Huang; Caixia, Qiu; Fangting, Zhang; Ningxin, He; Xiangli, Zhuang; Jian, Zheng.
Título: Systematic review and meta-analysis of probiotics in the treatment of allergic rhinitis
Fuente: Allergol. immunopatol;50(3):24-37, 2022. ilus, graf, tab.
Idioma: en.
doi: 10.15586/aei.v50i3.507.
Resumen: Background The purpose of this meta-analysis is to systematically evaluate the efficacy of probiotics on allergic rhinitis (AR).Methods Collecting randomized controlled trials (RCTs) with probiotics as intervention measures for AR, two researchers independently screened the literature, extracted the data and evaluated the methodological quality of the included studies, and used RevMan 5.3 software for meta-analysis to observe the effects of probiotics on Rhinitis Quality of Life (RQLQ) scores, Rhinitis Total Symptom Scores (RTSS), blood eosinophil count, total and antigen-specific serum immunoglobulin E (IgE) levels by using the fixed- or the random-effects model to calculate the pooled risk for significant heterogeneity.Results A total of 2708 patients were included in 30 RCTs. Meta-analysis results showed that the RQLQ global scores (mean difference [MD] = −9.43; P < 0.00001), RQLQ nasal scores (MD = −1.52; P = 0.03), and RTSS nasal scores (MD = −1.96; P = 0.02) significantly improved in the probiotic group when compared with those in the placebo group. There was no significant difference in blood eosinophil count (MD = −0.09; P=0.82), RQLQ eye scores (MD = −1.45; P = 0.07), RTSS global scores (MD = −2.24; P = 0.26), RTSS eye scores (MD = −0.39; P = 0.31), total and antigen-specific serum IgE levels (MD = −0.04; P = 0.7 and MD = −0.08; P = 0.81) between the probiotic and the placebo group.Conclusion Compared with the placebo group, the quality of life and symptoms of patients with AR significantly improved in the probiotic group, thus providing a new potential method for the application of probiotics in AR. However, because of the limited evidence for the current study outcomes, the heterogeneity of research, and the differences in research results, more high-quality studies are needed to in the future (AU)
Descriptores: probióticos/uso terapéutico
rinitis alérgica/farmacoterapia
-inmunoglobulina E
calidad de vida
Límites: seres humanos
Tipo de Publicación: metaanálisis
revisión sistemática
Responsable: ES15.1 - BNCS


  3 / 1742 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Texto Completo
Id: 203461
Autor: Dan, Huang; Yan, Lv; Chuansen, Lu; Bo, Zhang; Zongjun, Fu; Yingliu, Huang.
Título: Mechanism of Rhizoma Coptidis in epilepsy with network pharmacology
Fuente: Allergol. immunopatol;50(3):138-150, 2022. ilus, graf, tab.
Idioma: en.
doi: 10.15586/aei.v50i3.489.
Resumen: Network pharmacology is a bioinformatics-based research strategy aimed at identifying drug actions and facilitating drug discovery. In this study, network pharmacology was used for exploring the anti-epileptic multi-target mechanism of Rhizoma Coptidis. The possible protein targets of Rhizoma Coptidis were predicted by constructing the pathway and network of drug targets. Then, the interaction of the main active components of Rhizoma Coptidis and predicted candidate targets were verified using molecular docking technology. Finally, nine active compounds were selected from Rhizoma Coptidis. A total of 68 targets associated with Rhizoma Coptidis treating epilepsy. The key targets were AKT1, IL6, VEGFA, and TP53. According to GO functional enrichment analysis, 289 items of biological process, 33 items of cellular component, and 55 items of molecular function were obtained. A total of 89 signaling pathways were identified through KEGG pathway enrichment analysis (P < 0.05), and HIF-1, TNF, and T-cell receptor signaling pathways were mainly related to epilepsy. Molecular docking showed quercetin and (R)-canadine combined well with the key targets. The active ingredient in Rhizoma Coptidis can regulate various signaling pathways, and have therapeutic effects on epilepsy (AU)
Descriptores: medicamentos herbarios chinos/farmacología
medicamentos herbarios chinos/uso terapéutico
epilepsia/farmacoterapia
fitoterapia
-simulación de acoplamiento molecular
transducción de señales
descubrimiento de fármacos
Límites: seres humanos
Responsable: ES15.1 - BNCS


  4 / 1742 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Texto Completo
Id: 203460
Autor: Zhirong, Du; Jia, Yin.
Título: Safety of an inactivated COVID-19 vaccine in patients with - wheat-dependent exercise-induced anaphylaxis
Fuente: Allergol. immunopatol;50(3):132-137, 2022. tab, graf.
Idioma: en.
doi: 10.15586/aei.v50i3.570.
Resumen: Background Inactivated vaccines against coronavirus disease-2019 (COVID-19) offer an effective public health intervention to mitigate this devastating pandemic. However, little is known about their safety in patients with wheat-dependent exercise-induced anaphylaxis (WDEIA).Methods We recruited 72 WDEIA patients and 730 healthy matched controls who received an inactivated COVID-19 vaccine. Participants were monitored for 4 weeks after each immunization for adverse reactions and completed questionnaires regarding local and systemic reactions at 7 and 28 days after each vaccination. For those who had received the COVID-19 vaccine prior to enrollment, adverse event data were obtained retrospectively.Results Local and systemic adverse events occurred at similar rates in the WDEIA group and the control group. In both groups, injection-site pain and fatigue were the most common local and systemic reactions, respectively. Compared with healthy controls, more allergic events were reported in the WDEIA group (after dose 1, 0.5% vs. 4.2%, p=0.019; after dose 2, 0% vs. 1.4%, p=0.089). Allergic reactions mainly manifested as rash, urticaria, and edema, which were mild and controllable. No serious allergic events were reported.Conclusions The adverse event profile of inactivated COVID-19 vaccine did not differ between WDEIA patients and healthy controls. The risk of allergic reactions in patients with WDEIA seems higher, but no anaphylaxis was reported, and the allergic reactions were controllable. Inactivated COVID-19 vaccines appear to be well-tolerated in WDEIA patients, but patients with potential allergy risks should be cautious (AU)
Descriptores: anafilaxia/epidemiología
anafilaxia/etiología
vacunas víricas/efectos adversos
infecciones por Coronavirus/prevención & control
neumonía vírica/prevención & control
hipersensibilidad al trigo
ejercicio físico
-gliadina
estudios retrospectivos
estudios de casos y controles
Límites: seres humanos
Responsable: ES15.1 - BNCS


  5 / 1742 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Texto Completo
Id: 203459
Autor: Ruenwilai, Parinya; Theerakittikul, Theerakorn; Chaiwong, Warawut; Phetsuk, Nittaya; Pothirat, Chaicharn; Liwsrisakun, Chalerm.
Título: The comparative effect of Leukotriene receptor antagonist add on therapy and step up inhaled Corticosteroid in partially controlled asthma: an open-labeled randomized controlled trial
Fuente: Allergol. immunopatol;50(3):125-131, 2022. ilus, graf, tab.
Idioma: en.
doi: 10.15586/aei.v50i3.553.
Resumen: Background No studies are comparing the impact of the add-on leukotriene-receptor antagonist (LTRA) with a step-up dose of inhaled corticosteroids (ICS) in partly controlled asthma patients with asthma control test (ACT) score ˂ 23.Objective To study the effect of LTRA add-on therapy in comparison to a step-up to medium dose of ICS in partially controlled asthma.Methods An open-labeled randomized controlled trial was conducted in asthma subjects with partly controlled asthma who had been in regular receipt of low dose ICS. All subjects were assessed for asthma using ACT, daytime and nighttime symptoms, rate of relievers used, spirometry, and impulse oscillometry (IOS) at 3 and 6 months. Subjects were randomized to receive daily oral LTRA 10 mg or step-up medium dose of ICS.Results Between June 2020 and January 2021, 50 participants were enrolled, all patients completing the study. After treatment, mean ACT scores were increased to more than 23 indicating well-controlled asthma in both groups, control being sustained throughout the whole 6-month study period (P ˂ 0.001). Within each group, ACT scores were improved by a minimal clinical important difference (MCID) ≥ 3 points at 6 months, compared to baseline values. There were significant decreases in nighttime and daytime symptoms, and the numbers of rescue relievers used in 4 weeks in both groups compared to baseline (P ˂ 0.001).Conclusions LTRA add-on therapy in partially controlled asthma patients is comparable with step-up to medium dose of ICS/LABA as regards asthma control (AU)
Descriptores: hormonas de la corteza suprarrenal/uso terapéutico
antiasmáticos/uso terapéutico
asma/farmacoterapia
-administración por inhalación
combinaciones de fármacos
antagonistas de los leucotrienos/uso terapéutico
leucotrienos/uso terapéutico
Límites: seres humanos
Tipo de Publicación: ensayo clínico controlado aleatorizado
estudio comparativo
Responsable: ES15.1 - BNCS


  6 / 1742 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Texto Completo
Id: 203458
Autor: Yao, Chen; Buming, Sun.
Título: PTPRO activates TLR4/NF-kB signaling to intensify lipopolysaccharide-induced pneumonia cell injury
Fuente: Allergol. immunopatol;50(3):119-124, 2022. graf.
Idioma: en.
doi: 10.15586/aei.v50i3.589.
Resumen: Background Protein tyrosine phosphatase receptor type O (PTPRO) belongs to the PTP (protein tyrosine phosphatase) family and is widely expressed in parenchymal cells, such as breast and lung epithelial cells. PTPRO has been shown to enhance inflammatory responses and has been implicated in the pathogenesis of inflammation-associated diseases. The role of PTPRO in pneumonia was investigated.Methods Human embryonic lung fibroblasts (HFL1) were treated with increasing concentrations of lipopolysaccharide at 5, 10, or 20 μg/mL to induce inflammatory and apoptotic injuries. Expression of PTPRO was detected by western blot. Inflammation and apoptosis were assessed by ELISA and flow cytometry assays, respectively.Results Lipopolysaccharide induced decreased cell viability, and increased inflammation and apoptosis in HFL1. PTPRO was upregulated in HFL1 post lipopolysaccharide treatment, and silencing of PTPRO enhanced lipopolysaccharide-induced cell viability of HFL1, and suppressed the inflammation and apoptosis. However, overexpression of PTPRO aggravated lipopolysaccharide-induced cytotoxicity in HFL1. Overexpression of PTPRO upregulated protein expression of TLR4 and p-p65 in lipopolysaccharide-induced HFL1, while knockdown of PTPRO reduced the level of p-IκBα to downregulate levels of TLR4 and p-p65.Conclusion PTPRO contributed to pro-inflammatory and pro-apoptotic effects on lipopolysaccharide-induced HFL1 through activation of TLR4/NF-κB signaling (AU)
Descriptores: neumonía/inducido químicamente
inflamación/inducido químicamente
-proteínas transportadoras/metabolismo
NF-kappa B/metabolismo
monoéster fosfórico hidrolasas/metabolismo
proteína tirosina fosfatasas similares a receptores de clase 1/metabolismo
proteína tirosina fosfatasas similares a receptores de clase 1/metabolismo
Límites: seres humanos
Responsable: ES15.1 - BNCS


  7 / 1742 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Texto Completo
Id: 203457
Autor: Fan, Yang; Wenming, Liu.
Título: Tricin attenuates the progression of LPS-induced severe pneumonia in bronchial epithelial cells by regulating AKT and MAPK signaling pathways
Fuente: Allergol. immunopatol;50(3):113-118, 2022. graf.
Idioma: en.
doi: 10.15586/aei.v50i3.587.
Resumen: Background Pneumonia is a continuous and widespread disease with higher incidence, the effects of it on human life can be fearful. Tricin has been demonstrated to take part in the progression and development of diseases. However, the function of Tricin and its related regulatory pathways remain unclear. This study was planned to investigate the effects of Tricin on severe pneumonia.Methods The cell viability was detected through CCK-8 assay. The TNF-α, IL-1β and IL-6 levels were assessed through ELISA and RT-qPCR. The levels of MDA, SOD and GSH were tested through corresponding commercial kits. The protein expressions were examined through western blot.Results In our study, the lipopolysaccharide (LPS) was firstly used to stimulate cell model for severe pneumonia. We discovered that Tricin had no toxic effects on BEAS-2B cells and the decreased cell viability induced by LPS was relieved by a dose-dependent Tricin treatment. Additionally, through ELISA and RT-qPCR, it was uncovered that Tricin reduced the LPS-induced inflammation through regulating TNF-α, IL-1β and IL-6. Furthermore, Tricin relieved LPS-induced oxidative stress through reducing MDA level and enhancing SOD and GSH levels. Finally, it was demonstrated that Tricin retarded LPS-activated AKT and MAPK pathways.Conclusion Our findings revealed that Tricin attenuated the progression of LPS induced severe pneumonia through modulating AKT and MAPK signaling pathways. This discovery might afford one novel sight for the treatment of severe pneumonia (AU)
Descriptores: lipopolisacáridos
neumonía/inducido químicamente
-células epiteliales/metabolismo
flavonoides
inflamación
interleucina-6/metabolismo
sistema de señalización de las MAP cinasas
proteína oncogénica v-akt/metabolismo
superóxido dismutasa/metabolismo
factor de necrosis tumoral alfa/metabolismo
Responsable: ES15.1 - BNCS


  8 / 1742 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Texto Completo
Id: 203456
Autor: Adilijiang, Kari; Zhihua, M; Zhayidan, Aili; Ayinuerguli, Adili; Nadire, Hairula; Abulaiti, Abuduhaer.
Título: Knockdown of EPSTI1 alleviates lipopolysaccharide-induced inflammatory injury through regulation of NF-kB signaling in a cellular pneumonia model
Fuente: Allergol. immunopatol;50(3):106-112, 2022. graf.
Idioma: en.
doi: 10.15586/aei.v50i3.581.
Resumen: Background Although early diagnosis, antibiotic therapies, corticosteroid application, and health care services are conventional managements for pneumonia, antibiotic resistance and adverse reactions remain as limitations for pneumonia treatment.Objectives The study attempted to evaluate the potential role of EPSTI1 against pneumonia and reveal its underlying mechanism.Methods Lipopolysaccharide (LPS) (5, 10, and 20 μg/mL) was applied in WI-38 cells to establish the in vitro pneumonia model. Knockdown of epithelial-stromal interaction 1 (EPSTI1) was performed by transfection with EPSTI1 siRNA (siEPSTI1) into LPS-treated cells. Cell Counting Kit-8 assays were implemented to measure cell viability, and apoptotic cells were detected using flow cytometry. Interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) were quantified using enzyme-linked immunosorbent assay (ELISA). Immunoblotting and quantitative real-time polymerase chain reaction (qRT-PCR) were conducted to quantify EPSTI1 expression, and proteins related to nuclear factor κ-light-chain-enhancer of activated B cell (NF-κB) signaling, including p-p65, p65, p-IκBα, and IκBα.Results EPSTI1 was highly expressed in LPS-treated WI-38 cells. Cell apoptosis was promoted, and cell viability was inhibited after being exposed to LPS. Besides, IL-1β, IL-6, and TNF-α were dramatically upregulated. Knockdown of EPSTI1 restored cell viability, inhibited cell apoptosis, and attenuated expressions of proinflammatory factors. Additionally, knockdown of EPSTI1 visibly decreased the increased ratios of p-p65/p65 and p-IκBα/IκBα induced by LPS. Knockdown of EPSTI1 alleviated inflammatory injury through the inactivation of the NF-κB pathway (AU)
Descriptores: neumonía/metabolismo
-inflamación/inducido químicamente
interleucina-6/metabolismo
lipopolisacáridos/efectos adversos
inhibidor alfa de NF-kappaB
NF-kappa B/metabolismo
células cultivadas
Límites: seres humanos
Responsable: ES15.1 - BNCS


  9 / 1742 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Texto Completo
Id: 203455
Autor: Chao, Cheng; Mehrabi Nasab, Entezar; Shamsadin Athari, Seyyed.
Título: Survey of immunopharmacological effects of botulinum toxin in cell signaling of bronchial smooth muscle cells in allergic asthma
Fuente: Allergol. immunopatol;50(3):93-100, 2022. ilus, graf.
Idioma: en.
doi: 10.15586/aei.v50i3.549.
Resumen: Background Asthma is a lung disease that has influenced more than 350 million people worldwide. Airway smooth muscle (ASM) spasm leads to airway hyperresponsiveness (AHR) and bronchial obstruction, which are clinical manifestations of an asthma attack. Botulinum toxin (BTX) is a bacteria toxin that acts as muscle relaxant and may have therapeutic effects on AHR and asthma.Objective In this study, the effect of BTX on AHR and related gene expressions was evaluated.Material and Methods An asthma mice model was developed which was treated with BTX in two ways: intranasally (IN) and via nebulization (N) (0.01, 0.1, and 1 U/mL and 10 U/mL, respectively) on days 25, 27 and 29. AHR was evaluated on days 24, 26, 28, and 30, and gene expressions were evaluated for TrkA, TrkB, M1ûM5, α7nAChR, TNF-α, and extracellular signal-regulated kinase 2 (ERK2) proteins. For histopathology of the lungs, perivascular and peribronchial inflammation, production of mucus, and goblet cell hyperplasia were studied.Results On day 24, treatment with BTX (for all doses) had no significant effect on AHR, but on days 26 and 28, AHR was decreased and this continued up to day 30 for all treated groups. Treatment with BTX had no significant effect on the gene expressions of TrkA, TrkB, M1ûM5, α7nAChR, TNF-α, and ERK2 proteins, perivascular inflammation, peribronchial inflammation, hyperplasia of the goblet cell and production of mucus. Besides, mice administered with 10 mg/mL BTX perished. The BTX therapy controlled asthma attacks by decreasing AHR and relaxation of ASMs.Conclusion However, BTX had no significant effect on airway inflammation and production of mucus. While using BTX, it is necessary to prescribe safe doses in order to prevent adverse reactions (AU)
Descriptores: asma/farmacoterapia
toxinas botulínicas/uso terapéutico
hiperreactividad bronquial/farmacoterapia
-ratones endogámicos BALB C
miocitos del músculo liso
transducción de señales
factores de necrosis tumoral/metabolismo
receptor nicotínico alfa 7 de acetilcolina/metabolismo
Límites: animales
ratones
Responsable: ES15.1 - BNCS


  10 / 1742 IBECS  
              first record previous record
selecciona
para imprimir
Texto Completo
Texto Completo
Id: 203454
Autor: Xin, Han; Yini, Wu; Yongwei, Zhuang; Jianmei, Zhang.
Título: Dexmedetomidine reduces dextran sulfate sodium (DSS)-induced NCM460 cell inflammation and barrier damage by inhibiting RhoA/ROCK signaling pathway
Fuente: Allergol. immunopatol;50(3):85-92, 2022. ilus, graf.
Idioma: en.
doi: 10.15586/aei.v50i3.569.
Resumen: Objective This study investigated the role of dexmedetomidine (DEX) in dextran sulfate sodium (DSS)-induced NCM460 cells.Material and Methods The viability and apoptosis of NCM460 cells treated with DEX with or without DSS were detected by CCK-8 and terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay. The level of inflammatory factors and expression of inflammation-related proteins, tight junction proteins and Ras homolog gene family, member A/Rho-associated coiled-coil containing protein kinase (RhoA/ROCK) signaling-related proteins in NCM460 cells treated with DEX and/or U46619 (RhoA/ROCK agonist) and/or DSS were detected by the respective enzyme-linked immunosorbent assay (ELISA) kits and Western blot analysis. The permeability of NCM460 monolayers was examined with transepithelial electrical resistance (TEER) assay.Results DEX had no effect on NCM460 cell viability. However, DEX improved the viability and barrier damage and suppressed the apoptosis and inflammation of DSS-induced NCM460 cells. Correspondingly, the expression of inflammation-related proteins was reduced and the expression of tight junction proteins was increased in DSS-induced NCM460 cells after treatment with DEX. In addition, RhoA/ROCK signaling was activated in NCM460 cells induced by DSS, which was suppressed by DEX. The protective effects of DEX on DSS-indued NCM460 cells were reversed by U46619 (AU)
Descriptores: 15-hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-ácido dienoico/farmacología
dexmedetomidina/farmacología
sulfato de dextrano/farmacología
-inflamación/metabolismo
transducción de señales
cinasas asociadas a rho/metabolismo
proteína de unión al GTP rhoA/metabolismo
células cultivadas
Límites: seres humanos
Responsable: ES15.1 - BNCS



página 1 de 175 va a la página                         
   


Refinar la búsqueda
  Base de datos : IBECS Formulario avanzado   
Buscar por : Formulario libre    Formulario básico

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud